Loading…
Ganfort is a brand name for Bimatoprost. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Verbatim from this product's EMA label. Tap a section to expand.
Posology Recommended dosage in adults (including elderly) The recommended dose is one drop of GANFORT in the affected eye(s) once daily, administered either in the morning or in the evening. It should be administered at the same time each day.
Existing literature data for GANFORT suggest that evening dosing may be more effective in IOP-lowering than morning dosing. 1). If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
Renal and hepatic impairment GANFORT has not been studied in patients with hepatic or renal impairment. Therefore caution should be used in treating such patients. Paediatric population The safety and efficacy of GANFORT in children aged 0 to 18 years has not been established.
No data are available. Method of administration 3 If more than one topical ophthalmic medicinal product is to be used, each one should be instilled at least 5 minutes apart. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced.
This may result in a decrease in systemic side effects and an increase in local activity.
Summary of the safety profile The adverse reactions reported in clinical studies using GANFORT were limited to those earlier reported for either of the single active substances bimatoprost and timolol. No new adverse reactions specific for GANFORT have been observed in clinical studies.
The majority of adverse reactions reported in clinical studies using GANFORT were ocular, mild in severity and none were serious. 5% of patients. Tabulated list of adverse reactions Table 1 presents the adverse reactions that have been reported during clinical studies with all GANFORT formulations (multi-dose and single-dose) or in the post-marketing period.
Possible adverse reactions are listed by MedDRA system organ class and are based on the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000) and not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Table 1:
List of adverse reactions with all GANFORT formulations (multi-dose and single-dose) System Organ Class Frequency Adverse reaction Immune system disorders Not known Hypersensitivity reactions 7 including signs or symptoms of allergic dermatitis, angioedema, eye allergy Psychiatric disorders Not known Insomnia2, nightmare2 Nervous system disorders Common Headache Not known Dysgeusia2, dizziness Eye disorders Very common Conjunctival hyperaemia.
Common Punctuate keratitis, corneal erosion2, burning sensation2, conjunctival irritation1, eye pruritus, stinging sensation in the eye2, foreign body sensation, dry eye, erythema of eyelid, eye pain, photophobia, eye discharge, visual disturbance2, eyelid pruritus, visual acuity worsened2, blepharitis2, eyelid oedema, eye irritation, lacrimation increased, growth of eyelashes.
Like other topically applied ophthalmic medicinal products, the active substances (timolol/ bimatoprost) in GANFORT may be absorbed systemically. No enhancement of the systemic absorption of the individual active substances has been observed.
Due to the beta-adrenergic component, timolol, the same types of cardiovascular, pulmonary and other adverse reactions as seen with systemic beta-blockers may occur. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.
2. g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta-blockers should be critically assessed and therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.
Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block. e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution. Respiratory disorders Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.
GANFORT should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk. Endocrine disorders Beta-adrenergic blocking medicinal products should be administered with caution in patients subject to spontaneous hypoglycemia or to patients with labile diabetes as beta-blockers may mask the signs and symptoms of acute hypoglycemia.
Beta-blockers may also mask the signs of hyperthyroidism. Corneal diseases 4 Ophthalmic β-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution. Other beta-blocking agents The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta-blocking agent.
1. • Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease. • Sinus bradycardia, sick sinus syndrome, sino-atrial block, second- or third degree atrioventricular block, not controlled with pace-maker.
Overt cardiac failure, cardiogenic shock.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Bimatoprost in European Union.
Know a brand we are missing in European Union? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Uncommon Iritis2, conjunctival oedema2, eyelid pain2, abnormal sensation in the eye1, asthenopia, trichiasis2, iris hyperpigmentation2, periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus, eyelid ptosis, enophthalmos, lagophthalmos and eyelid retraction1&2, eyelash discolouration (darkening)1.
Not known Cystoid macular oedema2, eye swelling, vision blurred2, ocular discomfort Cardiac disorders Not known Bradycardia Vascular disorders Not known Hypertension Respiratory, thoracic and mediastinal disorders Common Rhinitis2 Uncommon Dyspnoea Not known Bronchospasm (predominantly in patients with pre-existing bronchospastic disease) 2, asthma Skin and subcutaneous tissue disorders Common Blepharal pigmentation2, hirsutism2, skin hyperpigmentation (periocular).
Not known Alopecia, skin discolouration (periocular) General disorders and administration site conditions Not known Fatigue 1adverse reactions only observed with Ganfort single-dose formulation 2adverse reactions only observed with Ganfort multi-dose formulation 8 Like other topically applied ophthalmic drugs, GANFORT (bimatoprost/timolol) is absorbed into the systemic circulation.
Absorption of timolol may cause similar undesirable effects as seen with systemic beta-blocking agents. The incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. 2. 4)1, keratitis1, blepharospasm2, retinal haemorrhage2, uveitis2, Cardiac disorder Atrioventricular block1, cardiac arrest1, arrhythmia1, cardiac failure1, congestive heart failure1, chest pain1, palpitations1, oedema1 Vascular disorders Hypotension1, Raynaud’s phenomenon1, cold hands and feet1 Respiratory, thoracic and mediastinal disorders Asthma exacerbation2, COPD exacerbation2, cough1 Gastrointestinal disorders Nausea1,2, diarrhoea1, dyspepsia1, dry mouth1, abdominal pain1, vomiting1 Skin and subcutaneous tissue disorders Psoriasiform rash1 or exacerbation of psoriasis1, skin rash1 Musculoskeletal and connective tissue disorders Myalgia1 Reproductive system and breast disorders Sexual dysfunction1, decreased libido1 General disorders and administration site conditions Asthenia1,2 Investigations Liver function tests (LFT) abnormal2 1 adverse reactions observed with timolol 2 adverse reactions observed with bimatoprost Adverse reactions reported in phosphate containing eye drops Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
The response of these patients should be closely observed. 5). Anaphylactic reactions While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual dose of adrenaline used to treat anaphylactic reactions.
g. timolol, acetazolamide) after filtration procedures. g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol. Hepatic In patients with a history of mild liver disease or abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin at baseline, bimatoprost had no adverse reactions on liver function over 24 months.
There are no known adverse reactions of ocular timolol on liver function. Ocular Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid or periocular skin and increased brown iris pigmentation since these have been observed during treatment with bimatoprost and GANFORT.
Increased iris pigmentation is likely to be permanent, and may lead to differences in appearance between the eyes if only one eye is treated. After discontinuation of GANFORT, pigmentation of iris may be permanent. 2%. 5% and did not increase following 3 years treatment.
The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. The long-term effects of increased iridial pigmentation are not known. Iris colour changes seen with ophthalmic administration of bimatoprost may not be noticeable for several months to years.
Neither nevi nor freckles of the iris appear to be affected by treatment. Periorbital tissue pigmentation has been reported to be reversible in some patients. Macular oedema, including cystoid macular oedema, has been reported with GANFORT.
g. intraocular surgery, retinal vein occlusions, ocular inflammatory disease and diabetic retinopathy). g. uveitis) because the inflammation may be exacerbated. Skin 5 There is a potential for hair growth to occur in areas where GANFORT solution comes repeatedly in contact with the skin surface.
Thus, it is important to apply GANFORT as instructed and avoid it running onto the cheek or other skin areas. Excipients The preservative in GANFORT, benzalkonium chloride, may cause eye irritation. Contact lenses must be removed prior to application, with at least a 15-minute wait before reinsertion.
Benzalkonium chloride is known to discolour soft contact lenses. Contact with soft contact lenses must be avoided. Benzalkonium chloride has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Therefore monitoring is required with frequent or prolonged use of GANFORT in dry eye patients or where the cornea is compromised.
Other conditions GANFORT has not been studied in patients […]